SYNTHOS RESEARCH

Synthos Research · Health & longevity · all questions · the Conviction Board

Are GLP-1 stocks still a buy?

The science panel rates the GLP-1 story 76/100 (durable, expanding indications) while the trade sits at the 55th percentile — a Frontier Gap of +21: still half-priced by our measure. Expert conviction: 91/100. Our LLY and NVO deep dives carry the per-name verdicts.

Synthos Score (parent prediction): 76/100 · graded in public

Synthos Research · synthosresearch.com · as of July 6, 2026 · distilled from 53,000+ dated, attributed expert claims, weighted by verified track record · updated weekly

Want the full picture? The complete call — the dialectic, what would change our mind, and the live change-log — is on the prediction page. Track it and we'll email you the moment it moves.

Related questions

How do I invest in longevity?What do longevity scientists actually agree on?Is the GLP-1 hype justified by the science?Will AI transform drug discovery?